SPRYCEL 140MG TABLETS| DASATINIB | MHP

1
SPRYCEL 140MG TABLETS DASATINIB MHP

• Million-Health-pharmaceuticals

2
DESCRIPTION

• Sprycel 140mg is a second-generation receptor
  Tyrosine kinase inhibitor. Which binds to Abl
  with less stringent conformational needed so it
  exhibits increased effectiveness compared to
  Imatinib even though with less selectivity.
  Unlike most RTK inhibitors, Sprycel 140mg linked
  the active conformation of Bcr-Abl. Is required
  to treat patients with some Imatinib resistant
  forms of CMLSprycel 140mg which used as
  prescription drug under the guidance of doctor.

3
INDICATION

• Sprycel 140mg is used for the treatment for
  Chronic Myeloid Leukaemia Recently diagnosed
  adults with Philadelphia chromosome-positive
  (Ph) chronic myeloid leukaemia (CML) in chronic
  phase.Severe, increased, or myeloid or lymphoid
  blast phase Ph CML with resistance or
  intolerance to prior therapy including
  imatinib.Sprycel 140mg is used for the treatment
  for Acute Lymphoblastic Leukaemia Philadelphia
  chromosome-positive (Ph) acute lymphoblastic
  leukaemia (ALL) with resistance or intolerance to
  prior therapy

4
MECHANISM OF ACTION

• Sprycel 140mg is used for the treatment for
  Chronic Myeloid Leukaemia Recently diagnosed
  adults with Philadelphia chromosome-positive
  (Ph) chronic myeloid leukaemia (CML) in chronic
  phase.Severe, increased, or myeloid or lymphoid
  blast phase Ph CML with resistance or
  intolerance to prior therapy including
  imatinib.Sprycel 140mg is used for the treatment
  for Acute Lymphoblastic Leukaemia Philadelphia
  chromosome-positive (Ph) acute lymphoblastic
  leukaemia (ALL) with resistance or intolerance to
  prior therapy

5
SPRYCEL 140MG TABLETS
6
PRODUCTS DEATIALS

• Brand Sprycel Ingredients Dasatinib Strength
  140mg Manufactured BMS India Pvt
  ltd Package 60 tablets

7
PHARMACOKINETICS

• Plasma protein binding is 96volume of
  distribution 2505 L Extensively metabolized in
  humans, mainly by the cytochrome P450 enzyme
  3A4.Dasatinib excreted through the
  feces. Half-life is 3-5 hours

8
DOSAGE MANAGMENT

• Newly diagnosed The prescribed dose for
  Chronic Myeloid Leukaemia is starting 100 mg PO
  qDay (morning or evening). The drug will be
  raised to 140 mg qDay if insufficient response.
  The prescribed dose for Advanced CML is starting
  140 mg PO qDay. The drug will increase to 180 mg
  qDay if insufficient reactions The prescribed
  dose for Acute Lymphoblastic Leukaemia is
  starting 140 mg PO qDay. The drug will increase
  to 180 mg PO qDay if insufficient reactions

9
PRECUATIONS

• When combination with chemotherapy the
  paediatric patients with Ph ALL treated, execute
  CBCs prior to initial of each block of
  chemotherapy and as clinically indicated during
  consolidation blocks of chemotherapy, do CBCs
  every 2 days until recovery  During treatment
  with Sprycel will causes Myelosuppression
  includes serious thrombocytopenia, neutropenia
  and Anemia may develop may manage by dose
  interruption, dose reduction, or stopping of
  treatment hematopoietic growth factor has been
  used with resistant myelosuppression.  Sprycel
  140mg will occur Hypokalaemia, hypomagnesemia,
  congenital QT interval prolongation, hepatic
  impairment  Use with caution the drug Sprycel
  140mg in patients who have or may develop
  prolongation of QT interval

10
SIDE EFFECTS

• Dyspnea  Anorexia  Arthralgia 
  Asthenia  Constipation  Dizziness 
  Musculoskeletal pain  Febrile neutropenia
  Thrombocytopenia Mucosal inflammation 
  Anemia  Skin rash  Infection  Nausea 
  Diarrhea  Headache  Haemorrhage Fatigue 
  Pyrexia

11
DRUG INTERACTION

• Sprycel 140mg concomitant use with CYP3A4
  inhibitors will have high Dasatinib plasma
  concentration.Sprycel 140mg concomitant use with
  CYP3A4 inducers will lowers Dasatinib plasma
  concentration.Sprycel 140mg concomitant use with
  antacids will lower Dasatinib plasma
  concentration.Sprycel 140mg concomitant use with
  H2 antagonists/proton pump inhibitors will lowers
  Dasatinib plasma concentration.Sprycel
  140mg concomitant use with CYP3A4 substrates will
  have their plasma concentration changed by
  Dasatinib.

12
MISSED DOSE

• If missed dose occurs, patients must consult with
  medical oncologist and follow the regular dosing
  schedule.

13
PREGNANCY

• Pregnancy category D Sprycel 140mg will resulted
  in fetal harm during pregnancy. Discuss with
  pregnant woman of the possible risk to a foetus.

14
LACTATION

• Avoid breast feeding during Sprycel treatment .

15
STORAGE

• Stored at 20C 25C

16
CONTACT US

• EMAIL millionhealthpharmaceuticals_at_gmail.com
• PHONE NO 91-9940472902
• WEBSIDE URLhttps//millionpharma.com/sprycel-140m
  g.php